Home / Market News / $NVCR

$NVCR news and market catalysts

The 15 most recent market catalysts affecting $NVCR, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

15 catalysts 5 high impact 9 bullish 3 bearish Biotechnology
Nov 14, 2026 Corporate Catalyst Neutral Impact 75
JAMA Network Open Publishes Results from Phase 3 PANOVA-3 Trial of Novocure's TTFields Therapy
Novocure reported that JAMA Network Open published a prespecified secondary analysis of its Phase 3 PANOVA-3 clinical trial, which evaluated TTFields therapy for pancreatic adenoca…
Nov 5, 2026 Corporate Catalyst Bullish Impact 55
Novocure Limited 12-Month Price Target Raised to $22.2
Novocure Limited has seen its average 12-month price target increased to $22.2 by a consensus of five analysts, representing a significant potential upside of 52% from its November…
Nov 1, 2026 Corporate Catalyst Bearish Impact 55
NovoCure Limited 12-Month Price Target Reduced to $21.33
Six covering analysts have lowered their average 12-month price target for NovoCure Limited from $25.71 to $21.33. This reduction suggests a more conservative outlook on the compan…
Oct 29, 2026 Corporate Catalyst Bearish Impact 85
NovoCure Reports Q3 2026 Financial Results
NovoCure announced its Q3 2026 financial results, revealing a net loss of $10.44 million, a substantial improvement from the $37.27 million loss in the prior year. Revenue also saw…
Oct 28, 2026 Corporate Catalyst Bullish Impact 65
Novocure and Verastem Oncology Announce Clinical Trial Collaboration for Pancreatic Cancer Treatment
Novocure and Verastem Oncology have announced a clinical trial collaboration to investigate a combination therapy for locally advanced pancreatic cancer. This is a significant deve…
Oct 1, 2026 Corporate Catalyst Bullish Impact 75
Japan’s Ministry Of Health, Labour And Welfare Approves Novocure's Optune Pax To Treat Adults With Unresectable Locally Advanced Pancreatic Cancer
Novocure received approval from Japan's Ministry of Health, Labour and Welfare for its Optune Pax device to treat unresectable locally advanced pancreatic cancer. This is a signifi…
Sep 1, 2026 Corporate Catalyst Bearish Impact 65
Novocure Reported Unauthorized Systems Access In Mid-August 2026, Exposing Internal Patient ID Numbers For Over 1,400 U.S. Records; No Medical Device Access Obtained, Operations, Systems Fully Functional
The unauthorized systems access at Novocure, exposing patient ID numbers, is a significant corporate catalyst. While operations remain functional and medical devices were not compr…
Jul 24, 2026 Corporate Catalyst Bullish Impact 85
NovoCure's Strongest Quarter Ever Isn't Enough to Stop NVCR Stock From Sliding
NovoCure announced impressive Q2 2026 results, surpassing analyst expectations for both revenue and earnings, and subsequently raised its full-year 2026 revenue and adjusted EBITDA…
Jul 23, 2026 Corporate Catalyst Bullish Impact 55
HC Wainwright & Co. Maintains Buy on NovoCure, Raises Price Target to $52
HC Wainwright & Co. analyst Emily Bodnar maintained a 'Buy' rating on NovoCure and raised the price target from $46 to $52. This action signals a continued bullish sentiment from a…
Jul 23, 2026 Corporate Catalyst Bullish Impact 65
12 Health Care Stocks Moving In Thursday's Intraday Session
This 8-K filing, presented as a Benzinga article, highlights significant intraday price fluctuations for a selection of healthcare stocks. The primary drivers identified for some o…
Jul 23, 2026 Corporate Catalyst Bullish Impact 85
NovoCure shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 sales guidance above estimates.
This headline represents a significant positive corporate catalyst for NovoCure. Better-than-expected earnings and, more importantly, a raised long-term sales guidance (FY26) signa…
Jul 23, 2026 Corporate Catalyst Neutral Impact 85
Transcript: NovoCure Q2 2026 Earnings Conference Call
NovoCure's Q2 2026 earnings call transcript reveals record net revenues of $184 million, a 16% year-over-year increase, driven by growth in Optune Gio, Lua, and Pax. The company al…
Jul 23, 2026 Corporate Catalyst Bullish Impact 75
NovoCure Raises FY2026 Sales Guidance from $690.000M-$710.000M to $710.000M-$725.000M vs $708.743M Est
NovoCure (NVCR) has filed an 8-K to announce an upward revision to its fiscal year 2026 sales guidance. The new range of $710 million to $725 million is higher than the previous $6…
Jul 23, 2026 Corporate Catalyst Bullish Impact 92
NovoCure Q2 EPS $(0.13) Beats $(0.33) Estimate, Sales $183.584M Beat $172.437M Estimate
NovoCure's Q2 earnings report shows a significant beat on both EPS and sales estimates, with losses narrowing considerably compared to the previous year. This indicates stronger op…
Jul 13, 2026 Corporate Catalyst Neutral Impact 55
JP Morgan Reinstates Neutral on NovoCure, Announces $17 Price Target
JP Morgan analyst Jessica Fye has reinstated coverage on NovoCure (NVCR) with a 'Neutral' rating and a $17 price target. This event is significant because analyst ratings and price…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.